Substance in grapes prevents agglomeration of a mutant protein that leads to cancer

June 27, 2018, Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)
(1) Resveratrol inhibits wild-type and mutant p53C aggregation in vitro. (2) Mutations in p53 protein in cancer cells are directly associated with amyloid aggregation. (3) Resveratrol impairs the formation of p53 amyloid-aggregates in MDA-MB-231 and HCC-70 human breast cancer cells and reduces cell migration and proliferation. (4) However, in the absence of this bioactive compound, massive nuclear accumulation of the aggregates occurs, increasing cancer aggressiveness and progression. Credit: Danielly C. Ferraz da Costa

Researchers at the Federal University of Rio de Janeiro (UFRJ) and the State University of Rio de Janeiro (UERJ) have made a discovery that could lead to the development of a treatment against more than half of breast cancer cases. Using resveratrol, a bioactive compound found in grapes and red wine, scientists were able for the first time to inhibit the agglomeration of mutant versions of the p53 protein, a structure present in about 60 percent of tumors, and to prevent migration and proliferation of breast cancer cells.

The potential anti-cancer effects of have been known for years, but to date, no study has been able to show that the substance can act to reduce tumors caused by the aggregation of the mutant form of . The Brazilian scientists are the first to obtain this result in the laboratory.

Because they are found in more than half of malignant tumors, amyloid aggregates of mutant p53 are considered novel strategic targets in the fight against cancer. In its normal, unmutated version, the protein is responsible for the suppression of cells, and for this reason is often referred to as "guardian of the genome." A mutant p53, however, can lose that function and gain others, sequestering its normal counterparts and contributing to the formation of amyloid aggregates, structures of difficult degradation and rapid growth. Some are extremely pathogenic, while others are harmless.

The laboratory of Professor Jerson Lima Silva has been investigating the amyloid aggregation of p53 for two decades. The main goal of this group is to understand the mechanisms that allow aggregates of mutant p53 to contribute to cancer and to find an effective way to prevent it from forming.

"The findings bring scientists closer to the development of a drug capable of acting directly on the amyloid aggregation of the mutant p53," says Danielly C. Ferraz da Costa, a co-author of the study, from the Institute of Nutrition of UERJ and a member of the INBEB. She began studying the properties of resveratrol for her doctoral thesis, and by 2012 had already investigated the anticancer protection by resveratrol in lung tumor cells.

The researchers applied fluorescence spectroscopy techniques in vitro to test the antitumor potential of resveratrol in aggregations of wild and mutant p53. In addition, they used immunofluorescence co-localization assays to test the action of the substance on breast cancer cells with different p53 mutants (MDA-MB-231 and HCC-70) and normal p53 (MCF-7). Decreased aggregation of mutated p53 was observed in tumors implanted in mice. The group is now studying various molecules derived from resveratrol that can be used in therapy against tumors containing mutated p53.

The paper, titled "Resveratrol prevents p53 in vitro and in ," is published online in Oncotarget.

Explore further: The genome guardian turns to the dark side: Opportunity for drug discovery against cancer?

More information: "Resveratrol prevents p53 aggregation in vitro and in breast cancer cells" Oncotarget (2018). DOI: 10.18632/oncotarget.25631 , http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=25631&path%5B%5D=80217

Journal reference: Oncotarget search and more info website

Provided by: Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)

12 shares

Related Stories

The genome guardian turns to the dark side: Opportunity for drug discovery against cancer?

June 1, 2018
Abnormal changes in the p53 protein are associated with many cancers. In fact, the gene that codes the p53 protein is the one most frequently mutated in human cancers. The protein, known as the guardian of the genome, has ...

Red wine ingredient resveratrol stops breast cancer growth

September 29, 2011
Cheers! A new research report appearing in the October 2011 issue of The FASEB Journal shows that resveratrol, the "healthy" ingredient in red wine, stops breast cancer cells from growing by blocking the growth effects of ...

A sip of resveratrol and a full p53: Ingredients for a successful cell death

November 13, 2012
Researchers at the Universidade Federal in Rio de Janeiro in Brazil have found that introduction of a normal copy of the p53 gene in p53-defective cancer cell lines makes these cells sensitive to the anti-tumor proprieties ...

Prions and cancer: A story unfolding

June 25, 2012
Prions, the causal agents of Mad Cow and other diseases, are very unique infectious particles. They are proteins in which the complex molecular three-dimensional folding process just went astray. For reasons not yet understood, ...

Combination breast cancer therapy targets tumor cells and the blood vessels that feed them

March 26, 2018
Each day, normal human cell tissues express a protein known as p53 that wages war against potential malignancies. However, between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53 that helps ...

Recommended for you

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.